1600511-80-5

Basic information

• Product Name: 2,5-dichloropyrido[3,4-b]pyrazine
• Synonyms: 2,5-dichloropyrido[3,4-b]pyrazine
• CAS NO: 1600511-80-5
• Molecular Weight: 200.027
• Mol File: 1600511-80-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2,5-dichloropyrido[3,4-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dichloropyrido[3,4-b]pyrazine(1600511-80-5)
• EPA Substance Registry System: 2,5-dichloropyrido[3,4-b]pyrazine(1600511-80-5)

Safety Data

• Hazardous Substances Data: 1600511-80-5(Hazardous Substances Data)

Usage

Structure

Heterocyclic aromatic compound with a pyrido[3,4-b]pyrazine core structure

Application

Used as a building block in the synthesis of pharmaceuticals, agrochemicals, and materials science

Precursor

Potential precursor in the production of biologically active compounds

Properties

Shows promising antitumor and antiviral properties

Drug Candidate

Identified as a potential drug candidate for the treatment of various diseases

Research Interest

Important target for further research and development in medicinal chemistry

Upstream product

• 39217-08-8 2-chloropyridine-3,4-diamine 

Downstream Products

• 1600507-14-9 (R)-5-Amino-3-(2,3-difluoro-5-((2-hydroxypyrido[3,4-b]pyrazin-5-yl)amino)phenyl)-3,6,6-trimethyl-3,6-dihydro-2H-1,4-thiazine 1,1-dioxide 
• 1624604-78-9 (4S,6S)-4-(2,3-difluoro-5-((2-methoxypyrido[3,4-b]pyrazin-5-yl)amino)phenyl)-4-methyl-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine 
• 1624603-22-0 N-(3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-2-methoxypyrido[3,4-b]pyrazin-5-amine 

Relevant articles and documents

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.